Date: 2014-03-17
Type of information: Grant
Company: Karo Bio (Sweden)
Investors: Vinnova (Sweden)
Amount: 1 million SEK (€0.11 million)
Funding type: grant
Planned used: The grant is awarded through the Forska & Väx program to finance toxicity and safety pharmacology studies of an ER-beta agonist. In previous studies, the compound has been shown to significantly reduce tumor size in preclinical models of mesothelioma and other types of cancer with poor prognosis.
Others: * On March 17, 2014, Karo Bio has announced that it will be awarded 1 million SEK from the Sweden Innovation Agency Vinnova for the preclinical development of an ER-beta agonist for the treatment of multiple cancers.
Therapeutic area: Cancer - Oncology
